Cetuximab & Panitumumab
Erbitux · Vectibix · Anti-EGFR antibody
TRPM6 magnesium wasting.
LYTE
MildOpen →
FGFR inhibitor
Futibatinib
Lytgobi · Futi
An irreversible FGFR1-4 inhibitor — same on-target hyperphosphatemia signature as the class.
ModerateFGFR inhibitor · approved 2022
FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma
Signature kidney injury
Electrolyte Wasting
Representative incidence85%
Hyperphosphatemia is the most common adverse event, reported in the large majority of patients in the pivotal FOENIX-CCA2 trial (~85% any grade, most low-grade); it is on-target, dose-related, and confirmed as a pharmacodynamic effect in first-in-human work.
Source: Goyal et al., N Engl J Med 2023
Mechanism of kidney injury
Covalent FGFR1 inhibition blocks FGF23-driven suppression of proximal-tubular phosphate reabsorption, increasing reabsorption and raising serum phosphate — the shared on-target class mechanism. Persistent elevation with a high calcium-phosphate product carries the same nephrocalcinosis/ectopic-calcification risk as other FGFR inhibitors.
Clinical presentation
Asymptomatic hyperphosphatemia detected on labs early in therapy; potential mineral-metabolism disturbance and ectopic calcification with sustained elevation. Nail toxicity, alopecia, and dry mouth are common non-renal effects.
Onset
Early — within the first cycles.
Reversibility
Reversible
Anticancer mechanism
Irreversible (covalent) pan-FGFR1-4 inhibitor; approved for FGFR2-fusion/rearrangement-positive intrahepatic cholangiocarcinoma.
Management
Phosphate binders and dietary restriction for phosphate above threshold; interrupt and dose-reduce for higher/persistent levels per label; discontinue for persistent hyperphosphatemia despite optimal management.
Risk factors
- Pre-existing CKD
- High dietary phosphate
- Elevated calcium-phosphate product
Prevention
- Serum phosphate monitoring
- Low-phosphate diet when phosphate rises
- Protocol-based dose modification
Note · Newer agent; renal data center on on-target hyperphosphatemia. Conservative interpretation of the high any-grade rate.
Clinical depth
Renal dose adjustment
No starting-dose change for mild-moderate renal impairment; severe impairment/dialysis not well studied. Phosphate-guided modification, not a CrCl rule, governs dosing.
Dialyzability & ESKD dosing
Highly protein-bound oral small molecule; not expected to be appreciably dialyzed. No validated ESKD dosing; phosphate-based PD monitoring is confounded in ESKD.
Differential diagnosis
On-target hyperphosphatemia (early, isolated, dose-related) vs CKD hyperphosphatemia vs tumor lysis. As with the class, the temporal pattern and absence of concurrent AKI point to the drug.
Monitoring
- Serum phosphate at baseline and periodically (frequently during early cycles)
- Serum calcium and calcium-phosphate product
- Ophthalmologic exams for retinal disorders; routine creatinine
Key trials & series
- FOENIX-CCA2 (registrational FGFR2-rearranged intrahepatic cholangiocarcinoma)
- Bahleda 2020 first-in-human phase 1 (hyperphosphatemia as PD effect)
Clinical pearls
- Newer agent, but the renal story is the familiar FGFR-class hyperphosphatemia — the high ~85% any-grade rate is mostly low-grade and manageable.
- Manage with diet and binders before dose changes; reserve interruption for higher thresholds.
- Track the calcium-phosphate product to limit nephrocalcinosis/ectopic-calcification risk.
Where it strikes
Nephron segments
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Injury signatures
Electrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of fgfr inhibitors.
Ophthalmic
Keratopathy, uveitis, retinopathy
- Central serous retinopathy
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Nail/skin changes, hand-foot syndrome
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkFutibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.Goyal L et al. · N Engl J Med 2023 · PMID 36652354Pivotal FOENIX-CCA2 trial: hyperphosphatemia the most common treatment-emergent adverse event.PMIDPhase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.Bahleda R et al. · Ann Oncol 2020 · PMID 32622884First-in-human study establishing hyperphosphatemia as an on-target pharmacodynamic effect.PMIDFGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.Katoh M et al. · Nat Rev Clin Oncol 2024 · PMID 38424198Review attributing class hyperphosphatemia to FGFR1 inhibition of renal phosphate excretion.PMIDManagement of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.Siefker-Radtke AO et al. · Eur Urol Open Sci 2023 · PMID 37101768Phosphate-management framework applicable to futibatinib hyperphosphatemia.PMIDSafety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis.Zheng X et al. · Front Oncol 2023 · PMID 36776367Class evidence framing hyperphosphatemia as the dominant FGFR-inhibitor adverse event.PMIDCalcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.Arudra K et al. · J Cutan Pathol 2018 · PMID 30021048Illustrates ectopic calcification from sustained FGFR-inhibitor hyperphosphatemia, the same risk applicable to futibatinib.